A Phase 2 Study of Nab-sirolimus and Letrozole in People With Endometrial Cancer


Full Title

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer


Researchers want to know if nab-sirolimus works well against endometrial cancer. The people in this study have endometrial cancer that has spread or came back after treatment.

Nab-sirolimus is a drug called a kinase inhibitor. Kinases are proteins that cancer cells need to survive and grow. By blocking these proteins, nab-sirolimus may help slow or stop the growth of your cancer.

If you join this study, you will get nab-sirolimus plus letrozole. Letrozole is a standard treatment for endometrial cancer. Nab-sirolimus is given intravenously (by vein) and letrozole is taken orally (my mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have endometrial cancer that spread or came back after treatment.
  • Have recovered from the serious side effects of prior cancer therapies before getting the study treatment.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Angela Green’s office at 646-888-6792.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID